Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 May;46(3):546-551.
doi: 10.1111/coa.13706. Epub 2021 Jan 9.

Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: A randomised trial

Jie Huang  1 , Li Yang  2 , Xihong Cao  3 , Wuqing Wang  4
Affiliations
Randomized Controlled Trial

Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: A randomised trial

Jie Huang et al. Clin Otolaryngol. 2021 May.

Abstract

Objectives: This study aimed to evaluate hearing improvement at different frequencies and the safety of intratympanic (IT) and intravenous (IV) administration of dexamethasone for sudden sensorineural hearing loss (SSNHL).

Methods: SSNHL patients were randomly divided into two groups within 72 hours after onset and received 24 days of dexamethasone therapy. Group A received IT dexamethasone once every other day for 24 days. Group B received IV dexamethasone for 12 days, followed by IT dexamethasone once every other day for the following 12 days. Hearing recovery and side effects were compared.

Results: Subgroup analysis was performed to look for variation in hearing improvement in high frequency, low frequency and overall hearing at different time points. There was no evidence of a difference in hearing outcomes between IT dexamethasone and sequential IV plus IT treatments. Side effects of steroids were observed within 90 days after treatment. The local adverse effects of IT injection were mild. The systemic side effects in group B were more serious than those in group A.

Conclusions: IT dexamethasone was safer than IV dexamethasone, and there was no evidence of a difference in hearing outcomes between IT dexamethasone and sequential IV plus IT treatments. It is necessary to make individualised treatment decisions according to the patient's condition.

Keywords: adverse effect; dexamethasone; intratympanic injection; sudden sensorineural hearing loss.

PubMed Disclaimer

References

REFERENCES

    1. Ahmadzai N, Kilty S, Cheng W, et al. A systematic review and network metaanalysis of existing pharmacologic therapies in patients with idiopathic sudden sensorineural hearing loss. PLoS One. 2019;14(9):e0221713.
    1. Qiang Q, Wu X, Yang T, Yang C, Sun H. A comparison between systemic and intratympanic steroid therapies as initial therapy for idiopathic sudden sensorineural hearing loss: a meta-analysis. Actaoto-laryngologica.2017,137(6):598-605.
    1. Siegel LG. The treatment of idiopathic sudden sensorineural hearing loss.Otolaryngologic clinics of North. America. 1975;8(2):467-473.
    1. Wilson WR, Byl FM, Laird N. The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double-blind clinical study[J]. Arch Otolaryngol. 1980;106(12):772-776.
    1. Silverstein H, Choo D, Rosenberg SI,, et al. Intratympanic steroid treatment of inner ear disease and tinnitus (preliminary report). Ear Nose Throat. 1996;75(8):468-567.

Publication types

LinkOut - more resources